A new antibiotic for pneumonia and skin infections
The FDA approved omadacycline (Nuzyra) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Omadacycline is a semisynthetic derivative tetracycline antibiotic, specifically designed to overcome tetracycline resistance and proven to be effective across Gram-positive, Gram-negative, and other drug-resistant strains.
To continue reading this article
Continue reading your article with a eMediNexus account.